In addition to the ciclesonide HFA nasal aerosol data presented at AAAAI, Sunovion also presented a poster titled, “A Post-Hoc Analysis of Asthma Control and Lung Function Following Treatment with ...

Active ingredient: Ciclesonide 80 µg/inhalation, 160 µg/inhalation; metered-dose inhaler. Indication: Maintenance treatment of asthma as prophylactic therapy in patients >12 years of age. Pharmacology ...

At all Walgreens locations, Alvesco will be available at no cost or reduced cost to eligible patients “Asthma is one of the country’s most common diseases, impacting 25 million individuals across the ...

Patients Taking ZETONNA Report Improved Quality Of Life Measures (RQLQ[S]) Associated With Seasonal Allergic Rhinitis MARLBOROUGH, Mass., Jul 30, 2012 (BUSINESS WIRE) -- Sunovion Pharmaceuticals Inc. ...

The study will enroll 400 patients with symptomatic coronavirus disease 201. A phase 3 study evaluating the efficacy and safety of ciclesonide inhalation aerosol (Alvesco) in non-hospitalized patients ...

With the COVID-19 pandemic, the world has suffered hundreds of thousands of deaths and tens of millions of cases. In order to contain this outbreak, new and already approved drugs are being tested. A ...

Data Presented at ACAAI Builds Upon Sunovion Legacy in Respiratory Therapies MARLBOROUGH, Mass., Saturday, November 5, 2011 - Sunovion Pharmaceuticals Inc. (Sunovion) today announced results from a ...

U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) filing to study the use of Alvesco in COVID-19 Study will evaluate the Safety and Efficacy of Alvesco ...

Ciclesonide is a corticosteroid currently approved in Europe for the treatment of inflammation that is the critical source of asthma symptoms. Data were recently presented at US conferences discussing ...

ZUG, Switzerland--(BUSINESS WIRE)--Covis Pharma B.V. (“Covis Pharma”), a global specialty pharmaceutical company, is pleased to announce an agreement with Walgreens, one of the largest drugstore ...